Key takeaways
- Early research gave LDN a plausible reason for interest: a small fibromyalgia trial found greater pain reduction than placebo. 2013 crossover trial.
- A later trial in 99 women did not show superior pain relief over placebo. Danish randomised trial.
- The 2026 INNOVA trial also found no clinically meaningful benefit for pain-related outcomes, despite generally good tolerability. INNOVA trial.
- Proposed effects on immune cells and pain signalling remain hypotheses, not proof of a treatment that “resets” immunity. Mechanistic review.
- Naltrexone blocks opioid receptors. It can interfere with opioid pain relief and precipitate withdrawal in someone who is opioid-dependent. FDA Revia prescribing information.
When pain has outlasted several treatments, an inexpensive medicine with enthusiastic patient reports is understandably interesting. Low-dose naltrexone, or LDN, has attracted exactly that kind of attention.
The most useful update is not another explanation of its proposed mechanism. It is that larger, newer fibromyalgia trials have tested the early promise, with less encouraging results. That changes how confidently LDN can be described, without dismissing anyone who reports feeling better.
Why did LDN become a chronic-pain talking point?
A small positive trial and a plausible biological explanation created a case for further research.
Naltrexone is established in addiction treatment. “LDN” describes use at substantially lower exposure for other purposes, including off-label treatment of chronic pain.
In 2013, a crossover trial in 31 women with fibromyalgia found a greater reduction in pain during naltrexone treatment than during placebo. Mood and satisfaction with life also improved, but fatigue and sleep did not. The authors called for larger parallel-group studies. Early trial.
Researchers have proposed effects on microglia, immune cells involved in signalling within the nervous system. Those ideas help explain why the medicine was worth investigating; they do not establish that a person’s pain is caused by a particular immune process or that LDN corrects it. Mechanistic review.
What did the newer trials find?
They did not reproduce a clear pain benefit over placebo.
| Study | Participants and follow-up | Main finding |
|---|---|---|
| 2013 crossover trial | 31 women with fibromyalgia | Greater pain reduction during LDN treatment |
| Danish parallel-group trial | 99 women; 12 weeks | No statistically significant superiority for pain |
| 2026 INNOVA trial | 98 women; followed for 12 months | No clinically meaningful benefit for pain-related outcomes |
Sources: 2013 trial, Danish trial, INNOVA.
INNOVA’s primary pain assessment was at three months, with longer follow-up also reported. Secondary findings were small or inconsistent. The Danish study raised an exploratory question about memory symptoms, but that is not evidence of an established cognitive benefit.
These studies were conducted in women with fibromyalgia. They do not settle every possible use of LDN, nor establish effectiveness across autoimmune diseases. They do make “proven fibromyalgia relief” an inaccurate description.
Can patient experience still matter when a trial is negative?
Yes, but improvement during treatment and improvement caused by treatment are different questions.
Symptoms fluctuate, expectations matter and other care can change at the same time. Placebo-controlled trials try to separate those influences from a medicine’s effect. A person’s report of improvement is worth hearing; it cannot by itself show who else will benefit.
For an individual treatment discussion, useful questions include what improvement would count, how it will be measured and what would prompt stopping. Our pregabalin review also separates evidence for particular pain conditions from claims about pain generally. Persistent fatigue is a separate assessment question, discussed in thyroid treatment and ongoing symptoms.
Why does the opioid interaction matter even at low exposure?
The word “low” does not remove naltrexone’s opioid-blocking action.
Codeine, tramadol, morphine, methadone and other opioids must be part of the prescribing discussion. Naltrexone may block needed analgesia; in someone physically dependent on opioids, starting it can trigger abrupt withdrawal. Trying to overcome the blockade with more opioid is dangerous. FDA prescribing information.
There is no safe universal washout timetable to copy from a blog. The prescriber needs to account for the opioid involved, dependence, other illness and potential emergency or surgical pain treatment. Commercial presentations and compounded preparations should also be checked individually, rather than assumed equivalent.
Do and don’t
Do: Ask which condition-specific evidence supports a proposed trial and disclose every opioid-containing medicine.
Don’t: Describe LDN as an immune reset, combine it with opioids on your own or turn an anecdote into a guarantee.
